$276 Million is the total value of Krensavage Asset Management, LLC's 23 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 4.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ENTA | Buy | ENANTA PHARMACEUTICALS INC | $26,393,000 | -17.0% | 730,308 | +3.3% | 9.55% | -20.4% |
UTHR | Buy | UNITED THERAPEUTICS CORP | $26,192,000 | +1.2% | 199,573 | +34.1% | 9.48% | -2.9% |
BXLT | New | BAXALTA INC | $22,744,000 | – | 721,800 | +100.0% | 8.23% | – |
TEVA | Buy | TEVA PHARMACEUTICAL-SP ADR | $21,063,000 | +15.0% | 373,062 | +20.4% | 7.62% | +10.3% |
OFIX | Buy | ORTHOFIX INTERNATIONAL NV | $20,596,000 | +18.8% | 610,247 | +16.6% | 7.46% | +14.0% |
IPXL | Buy | IMPAX LABORATORIES INC | $18,695,000 | -10.6% | 530,875 | +16.6% | 6.77% | -14.2% |
Buy | INDIVIOR PLC | $15,286,000 | +0.2% | 4,459,944 | +3.3% | 5.53% | -3.9% | |
HYH | Buy | HALYARD HEALTH INC | $15,242,000 | -13.7% | 535,943 | +22.9% | 5.52% | -17.2% |
Buy | AMGEN INC | $14,321,000 | +35.0% | 103,536 | +49.9% | 5.18% | +29.6% | |
CNMD | Buy | CONMED CORP | $13,106,000 | -15.3% | 274,528 | +3.4% | 4.74% | -18.7% |
MRK | Buy | MERCK & CO INC | $12,323,000 | -2.5% | 249,503 | +12.3% | 4.46% | -6.5% |
HRC | Buy | HILL-ROM HOLDINGS INC | $10,695,000 | -1.1% | 205,713 | +3.3% | 3.87% | -5.1% |
SCMP | Sell | SUCAMPO PHARMACEUTICALS-CL A | $10,495,000 | -34.0% | 528,175 | -45.4% | 3.80% | -36.6% |
RTIX | Buy | RTI SURGICAL INC | $10,387,000 | -9.2% | 1,828,672 | +3.3% | 3.76% | -12.8% |
DEPO | Buy | DEPOMED INC | $7,076,000 | -9.1% | 375,387 | +3.4% | 2.56% | -12.8% |
AGN | Buy | ALLERGAN PLC | $6,589,000 | -6.8% | 24,240 | +4.1% | 2.38% | -10.5% |
SPPI | Buy | SPECTRUM PHARMACEUTICALS INC | $6,449,000 | +11.7% | 1,078,502 | +27.8% | 2.33% | +7.2% |
IVC | Buy | INVACARE CORP | $5,822,000 | -23.9% | 402,382 | +13.8% | 2.11% | -27.0% |
Buy | BIOTA PHARMACEUTICALS INC | $5,090,000 | +50.1% | 2,570,577 | +56.9% | 1.84% | +44.0% | |
JNP | Sell | JUNIPER PHARMACEUTICALS INC | $3,295,000 | +9.9% | 279,717 | -14.6% | 1.19% | +5.5% |
DRAD | Buy | DIGIRAD CORP | $1,712,000 | -11.0% | 457,699 | +3.3% | 0.62% | -14.5% |
FURX | FURIEX PHARMACEUTICA CMN | $1,422,000 | 0.0% | 145,544 | 0.0% | 0.52% | -3.9% | |
THRX | Buy | THERAVANCE INC | $1,264,000 | -58.9% | 176,108 | +3.4% | 0.46% | -60.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
INVACARE CORP | 28 | Q3 2021 | 5.8% |
RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
MCKESSON CORP | 20 | Q3 2022 | 16.3% |
BIOGEN INC | 19 | Q3 2023 | 16.0% |
MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SCHEDULE 13G | 2024-02-27 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-15 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-16 |
13F-HR | 2023-02-15 |
13F-HR | 2022-11-15 |
13F-HR | 2022-08-16 |
13F-HR | 2022-05-17 |
13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.